ORIC
ORIC Pharmaceuticals, Inc.
Set alert
- YTD
- +12.96%
- 1 year
- -30.73%
- Open
- 8.87
- Prev close
- 8.99
- Mkt cap
- 957.75M
- Vol
- 2.44M
- Avg vol
- 1.57M
- EPS
- -1.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.28
- High
- 9.80
- Forward P/E
- -7.87
- Beta
- 0.98
- Short ratio
- 11.16
- Inst. own
- 123.41%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 12.96
- 200-d avg
- 11.13
- 1y target
- 21.64
Key statistics
- Market cap
- 1.37B
- Enterprise value
- 1.15B
- Trailing P/E
- 0.00
- Forward P/E
- -7.87
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.58
- EPS (TTM)
- -1.32
- Beta
- 0.98
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -68.83M
- Total cash
- 264.76M
- Total debt
- 6.00M
- Return on equity
- -39.80%
- Shares outstanding
- 103.65M
- Short % of float
- 15.91%
- 50-day average
- 12.96
- 200-day average
- 11.13
Analyst view
Consensus: strong buy
- Target (low)
- 14.00
- Target (mean)
- 21.64
- Target (high)
- 27.00
- Strong buy2
- Buy13
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.37887.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.38361 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | -0.35935 | -0.38 | -0.02 | -5.75% |
| May 4, 2026 | Mar 31, 2026 | -0.32075 | -0.34 | -0.02 | -6.00% |
| Feb 23, 2026 | Dec 31, 2025 | -0.34 | -0.30 | +0.04 | +11.76% |
| Nov 13, 2025 | Sep 30, 2025 | -0.41 | -0.33 | +0.08 | +19.51% |
| Aug 12, 2025 | Jun 30, 2025 | -0.46 | -0.47 | -0.01 | -2.17% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 5, 2026 | Leerink Partners | init | — | Outperform |
| Sep 23, 2026 | BTIG | init | — | Buy |
| Aug 10, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 8, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 15, 2026 | Goldman Sachs | up | — | Buy |
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- oricpharma.com
News
- BTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price Target
- Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14
- Oric Pharmaceuticals (NASDAQ:ORIC) Stock Crosses Below 200-Day Moving Average – Should You Sell?
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Stifel Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $18
- ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript
- Oric Pharmaceuticals' Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study
- ORIC Plans Global Phase 3 Redwood-1 Trial Of Enozertinib In 1L EGFR Atypical NSCLC In 1H 2027 After Phase 1b Showing 84% Confirmed Systemic ORR, 70% Confirmed Intracranial ORR
- ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial
- ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026
Your note
Sign in to keep a note on ORIC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHACKO JACOB M | Chief Executive Officer | Sale | Dec 15, 2025 | 581,711 |
| HEYMAN RICHARD A | Director | Conversion of Exercise of derivative security | Jul 23, 2026 | 244,972 |
| KUNKEL LORI ANNE | Director | Conversion of Exercise of derivative security | Dec 7, 2025 | 84,200 |
| MULTANI PRATIK S | Officer | Sale | Dec 15, 2025 | 68,149 |
| PISCITELLI DOMINIC G. | Chief Financial Officer | Conversion of Exercise of derivative security | Oct 19, 2026 | 69,828 |
| YOU ANGIE J. PH.D. | Director | Purchase | Jun 22, 2025 | 28,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Nextech Invest, Ltd. | 6.91% | 7,162,637 | 94.33M | Jun 29, 2026 |
| Blackrock Inc. | 6.58% | 6,823,973 | 89.87M | Jun 29, 2026 |
| EcoR1 Capital, LLC | 6.49% | 6,728,116 | 88.61M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 6.38% | 6,617,554 | 87.15M | Jun 29, 2026 |
| Viking Global Investors, L.P. | 4.95% | 5,126,762 | 67.52M | Jun 29, 2026 |
| State Street Corporation | 4.72% | 4,894,000 | 64.45M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.82% | 2,918,973 | 38.44M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.33% | 2,417,621 | 31.84M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.85% | 1,918,021 | 25.26M | Aug 30, 2026 |
| ACAP Strategic Fund | 1.79% | 1,850,470 | 24.37M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.48% | 1,533,122 | 20.19M | Jun 29, 2026 |
| T. ROWE PRICE QUANTITATIVE Mgmt Fd.S, INC.-T. Rowe Price Integrated U. | 1.22% | 1,261,301 | 16.61M | Jun 29, 2026 |